ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,213.49
0.51%
Dow Jones
38,675.68
1.18%
Gold vs US Dollar
2,302.57
0.00%
Brent Oil
82.765
0.00%
Bitcoin
63,889.04
-0.01%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Selvita Sa (0RKT)

  7. Selvita Sa (0RKT) News

Selvita (0RKT)

Selvita Sa
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0RKT
DateTimeSourceHeadlineSymbolCompany
06/03/202409:40UK RegulatoryRyvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual MeetingLSE:0RKTSelvita Sa
14/02/202418:12UK RegulatoryRyvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDSLSE:0RKTSelvita Sa
02/11/202315:02PR Newswire (US)Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual MeetingLSE:0RKTSelvita Sa
28/09/202218:17PR Newswire (US)Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate UpdateLSE:0RKTSelvita Sa
10/06/202210:54PR Newswire (US)Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) CongressLSE:0RKTSelvita Sa
08/03/202221:50PR Newswire (US)Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual MeetingLSE:0RKTSelvita Sa
11/06/202109:30PR Newswire (US)Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual 26th Annual Congress of the European Hematology As...LSE:0RKTSelvita Sa
28/05/202113:08PR Newswire (US)Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metas...LSE:0RKTSelvita Sa
04/01/202121:05PR Newswire (US)Selvita completes acquisition of Fidelta from GalapagosLSE:0RKTSelvita Sa
01/12/202012:10PR Newswire (US)Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be publish...LSE:0RKTSelvita Sa
10/09/202011:51PR Newswire (US)Selvita reports strong financial results for H1 2020 and a record backlogLSE:0RKTSelvita Sa
10/06/202017:58PR Newswire (US)Ryvu Therapeutics Reports First Quarter 2020 Financial ResultsLSE:0RKTSelvita Sa
02/06/202015:20PR Newswire (US)Ryvu Therapeutics Has Completed the Construction of the R&D Center for Innovative DrugsLSE:0RKTSelvita Sa
26/05/202007:24PR Newswire (US)Selvita Reports Financial Results for Q1 2020: Dynamic Increase in Backlog for 2020 and Strong Position on the MarketLSE:0RKTSelvita Sa
14/05/202014:30PR Newswire (US)Ryvu Therapeutics Announces Availability of Abstracts Regarding Phase 1/2 Study of SEL120 and SEL24/MEN1703 Accepted for Pres...LSE:0RKTSelvita Sa
27/04/202008:33PR Newswire (US)Selvita and Ardigen Will Receive Funding for the Development of an AI-based High-content Screening PlatformLSE:0RKTSelvita Sa
16/04/202007:12PR Newswire (US)Galapagos and Ryvu Announce Research CollaborationLSE:0RKTSelvita Sa
27/02/202011:00PR Newswire (US)Ryvu Therapeutics to Present Recent Data From Multiple Oncology Programs at AACR 2020 Annual MeetingLSE:0RKTSelvita Sa
07/11/201911:30PR Newswire (US)Selvita Q3 2019 Results: Accelerated Growth, 45 Percent Increase in Commercial Revenues and Strong Long-term OutlookLSE:0RKTSelvita Sa
06/11/201916:39PR Newswire (US)Ryvu Therapeutics Announces Presentations on CDK8 Inhibitor SEL120 at the 61st ASH Annual MeetingLSE:0RKTSelvita Sa
06/11/201913:00PR Newswire (US)Ryvu Therapeutics Reports Third Quarter 2019 Financial ResultsLSE:0RKTSelvita Sa
01/10/201915:00PR Newswire (US)Ryvu Therapeutics and Selvita Announce Registration of Corporate Split by the National Court Register of PolandLSE:0RKTSelvita Sa
06/09/201907:00PR Newswire (US)Selvita Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia o...LSE:0RKTSelvita Sa
05/09/201907:00PR Newswire (US)Selvita Reports Second Quarter and Half-year 2019 Financial ResultsLSE:0RKTSelvita Sa
03/09/201918:00PR Newswire (US)Polish Financial Supervision Authority Approves Selvita CRO Prospectus, Allowing Corporate Split Into Two Separately Listed C...LSE:0RKTSelvita Sa
03/09/201910:00PR Newswire (US)Selvita to Present at Upcoming Conferences in SeptemberLSE:0RKTSelvita Sa
25/07/201907:00PR Newswire (US)Selvita Appoints Setareh Shamsili, M.D., Ph.D., as Chief Medical OfficerLSE:0RKTSelvita Sa
22/05/201906:30PR Newswire (US)Selvita Reports First Quarter 2019 Financial Results and Provides Corporate UpdateLSE:0RKTSelvita Sa
13/05/201912:00PR Newswire (US)Selvita to Present at the UBS 2019 Global Healthcare Conference in New YorkLSE:0RKTSelvita Sa
28/03/201911:43PR Newswire (US)Selvita to Separate Oncology Therapeutics and Contract Research Business Units Into Two Global CompaniesLSE:0RKTSelvita Sa
 Showing the most relevant articles for your search:LSE:0RKT

Your Recent History

LSE
AGL
Angle
LSE
AAZ
Anglo Asian Mining
LSE
SRSP
Sirius Petroleum
LSE
SCLP
Scancell
LSE
POS
Plexus
LSE
AAU
Ariana Resources
LSE
LLOY
Lloyds Banking
LSE
INSG
Insig Ai
LSE
BT.A
Bt
LSE
TERN
Tern
LSE
BIRD
Blackbird
LSE
APTA
Aptamer
LSE
MIN
Minoan
LSE
IES
Invinity Energy Systems
LSE
ALBA
Alba Mineral Resources
LSE
THUS
Thus
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved